Abstract
Considering these results, we propose that maintaining ANL C<sub>trough</sub> ≥ 10.29ng/ml was important for achieving the response in advanced NSCLC patients treated with ANL.
Introduction
Anlotinib (ANL) is a multi-targeted receptor tyrosine kinase inhibitor (TKI) used as a third-line or later treatment for advanced non-small-cell lung cancer (NSCLC). Despite standard dosing, patients exhibit significant variability in drug exposure, leading to unpredictable clinical outcomes. This study explores the relationship between ANL trough plasma concentration ($C_{trough}$) and clinical efficacy to determine if therapeutic drug monitoring (TDM) can optimize treatment and maximize patient outcomes.
Methods
A prospective study was conducted with 52 Chinese patients with advanced NSCLC receiving ANL monotherapy. Blood samples were collected on day 43 to measure $C_{trough}$ using a novel ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method with zanubrutinib as an internal standard. Clinical response was evaluated via RECIST 1.1 criteria. Receiver Operating Characteristic (ROC) curves and the Youden index were utilized to identify the optimal $C_{trough}$ threshold for clinical response.
Results
The study confirmed high inter-patient variability in ANL exposure, with a coefficient of variation of 37.66%. The median $C_{trough}$ was 11.45 ng/ml, ranging from 3.69 to 26.36 ng/ml.
Statistical analysis revealed a clear exposure-response relationship. Patients achieving a Partial Response (PR) had a significantly higher median $C_{trough}$ (15.51 ng/ml) than those with Progressive Disease (PD) (7.44 ng/ml).
ROC analysis identified 10.29 ng/ml as the optimal threshold for predicting clinical response (AUC = 0.76). Patients with $C_{trough} \ge 10.29$ ng/ml achieved a disease control rate (DCR) of 96.67%, compared to 68.18% in the low-exposure group. While higher exposure increased the incidence of hand-foot syndrome (70.0% vs 36.36%) and TSH elevation, it did not significantly increase severe (Grade $\ge$ 3) toxicities.
Conclusion
Maintaining an ANL $C_{trough}$ of at least 10.29 ng/ml is critical for maximizing clinical response in advanced NSCLC. These findings support the implementation of TDM to personalize anlotinib dosing. Future multi-center studies are recommended to correlate these concentration thresholds with long-term survival outcomes like Progression-Free Survival (PFS) and Overall Survival (OS).
Summary updated